Dataset from An Open-label, Phase II Study to Determine Acute (After the First Dose Administration) and Chronic (After 28 Days of Treatment) Effects of the Sodium-glucose Co-transporter-2 (SGLT-2) Inhibitor Empagliflozin (BI 10773) (25 mg Once Daily) on Pre and Postprandial Glucose Homeostasis in Patients With IGT and, Type 2 Diabetes Mellitus and Healthy Subjects

An open-label, phase II study to assess the acute and chronic effects of empagliflozin (BI 10773)on fasting and postprandial glucose homeostasis in patients with IGT and type 2 diabetes mellitus and assess the acute effects of empagliflozin in healthy subjects.

本研究为一项开放标签II期临床试验，旨在评估恩格列净（empagliflozin，BI 10773）对糖耐量减低（Impaired Glucose Tolerance，IGT）及2型糖尿病患者的空腹与餐后糖稳态的急性及慢性影响，并评估恩格列净在健康受试者中的急性效应。